epitopes not only in A. fumigatus galactomannan but also in other bacteria and fungi.
Introduction
The detection of circulating galactomannan (GM) is a recognized criterion for the diagnosis of invasive aspergillosis [1, 2, 3]. The commercial kit Platelia TM Aspergillus enzyme immunoassay used in the clinics is based on an immunoassay with the rat IgM EB-A2 which has been shown to recognize oligosaccharides composed of at least four b-(1/5)-galactofuranosyl units [4, 5] . This epitope is present on the galactomannan, which is a major component of the Aspergillus cell wall and occurs as side chains of the linear mannan core. Despite a good sensitivity and specificity, the performance of the Platelia TM Aspergillus GM immunoassay has been shown to be far from perfect, particularly among patients receiving mold-active prophylaxis or treatment or pediatric patients [6, 7] . This is mainly due to the occurrence of false positives encountered for this test.
Many reasons have been proposed to be responsible for false positive results with the commercial GM test. First, some of the false positive results come from an erroneous operational use of the test [8] . Some other false positive data result from the presence of GM in the circulating fluid of the patient which was not linked to an Aspergillus infection: the major example is connected with the use of Tazocin TM (Piperacilin-Tazobacam) whose raw material utilized for the production of the antibiotics was contaminated by filamentous ascomycetes such as Penicillium or Aspergillus which both are source of GM. The use of Tazocin TM which is not contaminated by GM solved this problem [9] .
False positive data have been also associated with intake of contaminated food and enteral nutrition [10] . Similarly to Tazocin TM , a better purification of solutions containing low-molecular-weight organic acids which are produced by a fermentation process involving Aspergillus resolved these problems like in cases of false positivity due to the intravenous injection of sodium gluconate [11] . Other invasive fungal infections are suspected to be associated with the release of GM: (i) it has been demonstrated chemically that Penicillium secretes a polysaccharide with a b-(1/5)-galactofuranoside epitope similar to the one present in Aspergilli species [12] and that the GM test can be used to detect Penicillium marneffei infections (Huang et al, 2007) [13] ; (ii) a positivity of the ELISA test has been noticed with the yeasts Cryptococcus and Histoplasma while the presence of b-(1/5)-galactofuranoside units has not been reported in these yeast species. Some of the false positives still remain unexplained such as the positivity of multiple myeloma patients exempt of aspergillosis infections [14] .
The false positivity can also result from cross reactions knotted with the presence of different bacteria of the human microbiota including Escherichia coli [15] , Rhodococcus equi [16] , Corynebacterium jeikeium [15] and Bifidobacterium spp [17] .
They produce a galctofuranoside epitope also recognized by the EB-A2 mAb and may be responsible for false positivity in patients in the late phase of allogeneic hematopoietic stem cell transplantation with heavy gastrointestinal Graft vs Host disease [18] . Moreover, (i) N-glycans and glycolipids which do not bear the tetragalactofuranosyl moiety are recognized by this monoclonal antibody [19] and (ii) recent studies have shown that side chains of GM are not exclusively composed of linear b-(1/5)-galactofuranosyl units [20] but contain a certain amount of b-(1/6)-linked galactofuranosyl units attached to the mannan backbone [21, 22] .
All these data have raised some questions on the exact nature of the epitope recognized by the EB-A2 mAb and suggested that the mAb used in the commercial kit may recognize multiple carbohydrate epitopes, a classical fact with anticarbohydrate antibodies. The multiplicity of the epitopes recognized may be also a reason for the occurrence of some of the false positives reported in the literature which affects the performance of the test for the diagnosis of invasive aspergillosis.
Results & discussion
To reinvestigate the nature of the carbohydrate epitope recognized by the mAb EB-A2 a glycoarray composed of synthetic oligosaccharides with definite structures representing key fragments of the galactomannan of A. fumigatus was used. The selection of synthetic oligosaccharide derivatives 1e13 (Fig. 1A) for this study was based on the most recent definition of the galactofuranyl-containing structures of Aspergillus galactomannan. Oligosaccharides 1e13 were prepared [22, 23, 24] using pyranoside-into-furanoside rearrangement [25, 26] and biotynilation using an activated biotin derivative [27] 
Conclusion
This study indicates that the mAb EB-A2 used in the kit for the detection of the circulating GM for the diagnosis of aspergillosis, recognizes multiple epitopes that are all present in the native GM molecule. The multiplicity of the epitopes recognized by the mAb can be a major cause for the occurrence of false positive results which impacts the performance of the existing test. Substitution of EB-A2 mAb in the immune assay with an antibody capable of recognizing a larger epitope should increase the specificity of the assay and will facilitate the decision for the initiation of an antifungal therapy. Synthetic immunogens which contain the oligosaccharide ligands of necessary length and structure can be regarded as promising instruments for obtaining of monoclonal antibodies with required epitope specificity and affinity to GM [32, 33] which may be better adapted for the conception of a more specific test in the serological diagnosis of invasive aspergillosis.
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